Intellia pauses trials after serious liver event in gene therapy patient
NegativeFinancial Markets

Intellia Therapeutics has decided to pause its clinical trials following a serious liver event experienced by a patient undergoing gene therapy. This decision highlights the potential risks associated with innovative treatments and raises concerns about patient safety. The pause in trials could delay advancements in gene therapy, which has shown promise in treating genetic disorders, making it a significant moment for both the company and the field.
— Curated by the World Pulse Now AI Editorial System






